REAL-WORLD DOSING AND ADHERENCE IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH NABIXIMOLS IN GERMANY

被引：0
|
作者：
Freilich, J. [1 ]
Rodriguez-Rey, Delclaux M. [2 ]
Spelman, T. [3 ]
Yeramaneni, S. [4 ]
Drachenberg, C. [4 ]
机构：
[1] Parexel Int, Stockholm, AB, Sweden
[2] Parexel Int, London, England
[3] Karolinska Inst, Stockholm, Sweden
[4] Jazz Pharmaceut, Palo Alto, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD86
引用
收藏
页码：S376 / S376
页数：1
相关论文
共 50 条
  • [31] Real-world experience of ocrelizumab in multiple sclerosis patients in latin america
    Rojas, J.
    Patrucco, L.
    Fruns, M.
    Flores-Rivera, J.
    Carnero Contentti, E.
    Galleguillos, L.
    Alonso, R.
    Cristiano, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 548 - 548
  • [32] Real-World Fingolimod efficacy and safety in Emirati patients with multiple sclerosis
    Ceccarelli, Antonia
    Mifsud, Victoria
    Elhennawy, Rawan Yasser Gaber
    Benedetti, Beatrice
    Hussain, Syed
    Samples, Stephen
    NEUROLOGY, 2019, 92 (15)
  • [33] Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
    Ignacio Rojas, Juan
    Patrucco, Liliana
    Fruns, Manuel
    Hornung, Giesela
    Flores, Jose
    Carnero Contentti, Edgar
    Adrian Lopez, Pablo
    Pablo Pettinicchi, Juan
    Caride, Alejandro
    Galleguillos, Lorna
    Barahona, Jorge
    Diaz, Violeta
    Hernandez, Marianella
    Alonso, Ricardo
    Cristiano, Edgardo
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2021, 79 (04) : 305 - 309
  • [34] Safety and Effectiveness of Fingolimod in Real-World Multiple Sclerosis Portuguese Patients
    Ribeiro de Barros, Ariana Helena
    Fiadeiro Sequeira, Joao Paulo
    Lopes de Sousa, Ary Severino
    Chegancas Capela, Carlos Miguel
    Gomes Pedrosa, Rui Manuel
    dos Santos Manita, Manuel Alexandre
    CLINICAL NEUROPHARMACOLOGY, 2018, 41 (04) : 129 - 135
  • [35] Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
    Rodriguez-Leal, Francisco Alejandro
    Haase, Rocco
    Akguen, Katja
    Eisele, Judith
    Proschmann, Undine
    Schultheiss, Thorsten
    Kern, Raimar
    Ziemssen, Tjalf
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2019, 10 : 1 - 11
  • [36] Safety issues in multiple sclerosis patients treated with alemtuzumab in real world
    Oreja-Guevara, C.
    Guerra-Schulz, E.
    Minano-Guillamon, E.
    Carcamo Fonfria, A.
    Ortiz-Pica, M.
    Arenaza-Pena, A.
    Gonzalez-Suarez, I.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 920 - 921
  • [37] Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis
    Hersh, Carrie M.
    Gorritz, Magdaliz
    Chen, Chi-Chang
    Tuly, Rifat
    Gu, Yifan
    Gadkari, Abhijit
    Brown, Brandon
    Shao, Qiujun
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [38] Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study
    Menge, Til
    Rehberg-Weber, Karin
    Taipale, Kirsi
    Nastos, Ilies
    Jauss, Marek
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [39] Real-World Treatment Utilization and Effectiveness of OnabotulinumtoxinA in Multiple Sclerosis Patients Treated for Spasticity From the ASPIRE Study
    Bandari, Daniel S.
    Mayadev, Angeli
    Sakel, Mohamed
    Esquenazi, Alberto
    Zuzek, Aleksej
    Largent, Joan
    Francisco, Gerard E.
    TOXICON, 2022, 214 : S6 - S6
  • [40] A real-world data study of coronavirus-2019 disease severity in patients with multiple sclerosis treated with ocrelizumab
    Dillon, P.
    Waqar, A.
    Roumpanis, S.
    Martinec, M.
    Muros-Le Rouzic, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 103 - 104
12345